We all know that IHL is in a wonderful spot with its CBD and Psychedelic trials. Just want to share this report that Roth Capital has on Cybin which is NYSE listed.
What I like about this report is that it shows how well Roth research team understands the market and the competition (they have Buy rating on Cybin and Compass pathways). While Roth Investment Banking side would work with IHL for the listing on NASDAQ, this report demonstrates that their research (separated by a Chinese wall) is able to provide a solid report which would be read by instos and retail investors in this space. Further, their trading desk would obviously market IXHL to their clients who are interested in this space.
I would suggest you to read this report to get a big picture of the industry, the competitive landscape, the pros and cons of various Psychedelics options, delivery mechanisms etc.,. Also imagine very soon, these reports will be mentioning IXHL as part of the competition
https://drive.google.com/file/d/1nJnXE2qOuUt1i8PRJxj84kK0Ct3tVJAO/view
(Definitely not cross promoting Cybin!)
Industry news, page-101
-
- There are more pages in this discussion • 798 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)